Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 1/2013

01-03-2013 | Original Article

A novel missense mutation (N78D) in a family with von Hippel–Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts

Authors: S. Cingoz, R. B. van der Luijt, E. Kurt, M. Apaydin, I. Akkol, Mihriban Heval Ozgen

Published in: Familial Cancer | Issue 1/2013

Login to get access

Abstract

von Hippel–Lindau (VHL) disease is a hereditary tumor syndrome caused by mutations in the VHL tumor suppressor gene. In a family with VHL, we identified a novel missense mutation (N78D), which affects a fully conserved residue in the VHL protein. Interestingly, several other missense mutations reported at same codon in the VHL protein that might be associated with a low risk of renal cell carcinoma (RCC) but not pheochromocytoma appear to be associated with a VHL type 1 phenotype. At the moment, RCC is present in none of the affected mutation carriers in the family described here. In contrast to other missense changes at codon 78, the change in our VHL family is predicted to have a mild effect on VHL function, which apparently is insufficient to cause predisposition to RCC. Our findings suggest that the risk of RCC in VHL is attributable to the severity of the amino acid substitution at this particular codon in the VHL protein.
Appendix
Available only for authorised users
Literature
1.
Richards FM, Maher ER, Latif F, Phipps ME, Tory K, Lush M, Crossey PA, Oostra B, Gustavson KH, Green J, Turner G, Yates JRW, Linehan WM, Affara NA, Lerman M, Zbar B, Ferguson-Smith MA (1993) Detailed genetic mapping of the von Hippel–Lindau disease tumour suppressor gene. J Med Genet 30:104–107PubMedCrossRef
2.
Glenn GM, Daniel LN, Choyke P, Linehan WM, Oldfield E, Gorin MB, Hosoe S, Latif F, Weiss G, Walther M, Lerman MI, Zbar B (1991) Von Hippel–Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus. Hum Genet 87:207–210PubMedCrossRef
3.
Maher ER, Yates JRW, Ferguson-Smith MA (1990) Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J Med Genet 27:311–314PubMedCrossRef
4.
Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH (2003) von Hippel–Lindau disease. Lancet 361:2059–2067PubMedCrossRef
5.
Neumann HPH, Wiestler OD (1991) Clustering of features of von Hippel–Lindau syndrome: evidence for a complex genetic locus. Lancet 337:1052–1054PubMedCrossRef
6.
Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Hofler H, Latif F, Lerman MI, Zbar B, Neumann HPH (1995) Von Hippel–Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet 95:551–556PubMedCrossRef
7.
Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr (2001) von Hippel–Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10:1019–1027PubMedCrossRef
8.
Nordstrom-O’Brien M, van der Luijt RB, van Rooijen E, van den Ouweland AM, Majoor-Krakauer DF, Lolkema MP, van Brussel A, Voest EE, Giles RH (2010) Genetic analysis of von Hippel–Lindau disease. Hum Mutat 31:521–537PubMed
9.
Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER (2001) Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel–Lindau disease. Hum Mol Genet 10(10):1029–1038PubMedCrossRef
10.
Bangiyeva V, Rosenbloom A, Alexander AE, Isanova B, Popko T, Schoenfeld AR (2009) Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes. BMC Cancer 14(9):229CrossRef
11.
Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, Zbar B, Affara NA, Ferguson-Smith MA, Maher ER (1994) Identification of intragenic mutations in the von Hippel–Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 3(8):1303–1308PubMedCrossRef
12.
Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia YE, Lamiell J, Li H, Wei MH, Schmidt L, Tory K, Kuzman I, Stackhouse T, Latif F, Linehan WM, Lerman M, Zbar B (1995) Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66–75PubMedCrossRef
13.
Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann HPH, Tisherman S, Mulvihill JJ, Gross D, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, Boisson C, Richard S, Lips CHM, Linehan MW, Lerman M (1996) Germline mutations in the Von Hippel–Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8:348–357PubMedCrossRef
14.
Neumann HP, Bender BU (1998) Genotype-phenotype correlations in von Hippel–Lindau disease. J Intern Med 243(6):541–545PubMedCrossRef
15.
Forman JR, Worth CL, Bickerton GR, Eisen TG, Blundell TL (2009) Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel–Lindau disease and suggests molecular mechanisms of tumorigenesis. Proteins 77(1):84–96PubMedCrossRef
16.
Stebbins CE, Kaelin WG Jr, Pavletich NP (1999) Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284(5413):455–461PubMedCrossRef
17.
Liu J, Nussinov R (2008) Allosteric effects in the marginally stable von Hippel–Lindau tumor suppressor protein and allostery-based rescue mutant design. Proc Natl Acad Sci USA 105(3):901–906PubMedCrossRef
18.
Hes FJ, van der Luijt RB, Janssen ALW, Zewald RA, de Jong GJ, Lenders JW, Links TP, Luyten GPM, Sijmons RH, Eussen HJ, Halley DJJ, Lips CJM, Pearson PL, van den Ouweland AMW, Majoor-Krakauer DF (2007) Frequency of Von Hippel–Lindau germline mutations in classic and non-classic Von Hippel–Lindau disease identiWed by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe ampliWcation. Clin Genet 72:122–129PubMedCrossRef
19.
Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER (2007) Genotype-phenotype correlations in von Hippel–Lindau disease. Hum Mutat 28:143–149PubMedCrossRef
20.
Gossage L, Cartwright E, Eisen T, Bycroft MA (2010) Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 7(5):277–288PubMedCrossRef
21.
McNeill A, Rattenberry E, Barber R, Killick P, MacDonald F, Maher ER (2009) Genotype-phenotype correlations in VHL exon deletions. Am J Med Genet 149A:2147–2151PubMedCrossRef
22.
Gomy I, Molfetta GA, de Andrade Barreto E, Ferreira CA, Zanette DL, Casali-da-Rocha JC, Silva WA Jr (2010) Clinical and molecular characterization of Brazilian families with von Hippel–Lindau disease: a need for delineating genotype-phenotype correlation. Fam Cancer 9(4):635–642PubMedCrossRef
23.
Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43(4):295–305PubMedCrossRef
24.
Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B (1995) Cellular proteins that bind the von Hippel–Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res 55:4544–4548
25.
Kanno H, Shuin T, Kondo K, Ito S, Hosaka M, Torigoe S, Fujii S, Tanaka Y, Yamamoto I, Kim I, Yao M (1996) Molecular genetic diagnosis of von Hippel–Lindau disease: analysis of five Japanese families. Jpn J Cancer Res 87:423–428
26.
Clinical Research Group for VHL in Japan (1995) Germline mutations in the von Hippel–Lindau disease (VHL) gene in Japanese VHL. Hum Mol Genet 4:2233–2237
27.
Bailly M, Bain C, Favrot MC, Ozturk M (1995) Somatic mutations of Von Hippel–Lindau (VHL) tumor-supressor gene in european kidney cancers. Int J Cancer 63:660–664
28.
Maher ER, Webster AR, Richards FM, Green JS, Crossey PA, Payne SJ, Moore AT (1996) Phenotypic expression in von Hippel–Lindau disease: correlations with germline VHL gene mutations. J Med Genet 33:328–332
Metadata
Title
A novel missense mutation (N78D) in a family with von Hippel–Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts
Authors
S. Cingoz
R. B. van der Luijt
E. Kurt
M. Apaydin
I. Akkol
Mihriban Heval Ozgen
Publication date
01-03-2013
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2013
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-012-9586-7

Other articles of this Issue 1/2013

Familial Cancer 1/2013 Go to the issue

Letter to the Editor

Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation

Original Article

Contribution of bi-allelic germline MUTYH mutations to early-onset and familial colorectal cancer and to low number of adenomatous polyps: case-series and literature review

Original Article

An unusual BRCA mutation distribution in a high risk cancer genetics clinic

Original Article

Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer

Original Article

The spectrum of urological malignancy in Lynch syndrome

Original Article

The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits